Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-25 08:47 • The Motley Fool Neutral Axe Cap view: Selective

Elon Musk announced plans to give one SpaceX share to every American child under 18 (approximately 72 million children), valued at roughly $12 billion. The gift would represent only 1.8% of Musk's B shares and would not dilute existing shareholders since Musk can personally fund it. While long-term impacts are minimal given daily trading volumes of nearly 100 million shares, many child recipients may sell their shares at first opportunity.

Axe note: Elon Musk plans to hand over 1.8% of SpaceX shares to American children, sparking questions on share supply and market effects.

2026-10-25 08:30 • The Motley Fool Positive Axe Cap view: Selective

Both Nvidia and Micron are key players in the AI revolution, with Nvidia dominating AI chip manufacturing and Micron providing essential memory and storage solutions. While both stocks have delivered exceptional returns over five years, the article recommends Nvidia as the better buy due to its diversified AI portfolio and non-cyclical market position, whereas Micron faces vulnerability to memory price declines once supply normalizes.

Axe note: Nvidia’s broad AI dominance beats Micron’s cyclical memory bets for South African investors.

2026-10-25 08:26 • The Motley Fool Positive Axe Cap view: Selective

Amgen and Gilead Sciences are compared as dividend-paying biotech stocks. Amgen offers a higher yield (2.2%) and stronger product sales growth, while Gilead has a lower payout ratio (43.5% vs 60.9%) and better valuation metrics. The choice depends on investor priorities: Amgen suits yield-focused investors, while Gilead appeals to those prioritizing safety and value. Both stocks offer higher yields than the S&P 500.

Axe note: Two strong biotech dividend stocks show distinct profiles—yield-focused Amgen and value-minded Gilead.